Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.